验证一种新的特定于葡萄糖皮质激素的患者报告结果问卷 (类固醇PRO)
Susan Bridgewater1,2, Mwidimi Ndosi1,2, Jill Dawson3
1School of Health and Social Wellbeing, University of the West of England, Bristol, UK.
Annals of the rheumatic diseases
|November 10, 2023
概括
类固醇PRO是一种新的15项量表,可靠地测量葡萄糖皮质类药物治疗对风湿性疾病患者生活质量的影响.
科学领域:
- 类风湿病学 类风湿病学
- 心理测量 心理测量 心理测量
- 健康 结果 研究 研究 结果
背景情况:
- 葡萄糖皮质类药物是常见的炎症性类风湿病的治疗方法.
- 这些药物可以显著影响患者与健康相关的生活质量.
- 需要一个特定的工具来衡量这种影响.
研究的目的:
- 为了确定类固醇PRO尺度的尺度结构和心理特征.
- 开发一种专门用于类固醇治疗风湿性疾病的患者报告结果 (PRO) 工具.
主要方法:
- 在英国,美国,澳大利亚和新西兰,对946名使用葡萄皮质类药物治疗类风湿性疾病的成年患者进行了横截面调查.
- 分析涉及拉什测量模型,探索性因子分析 (EFA) 和对有效性和可靠性的假设测试.
- 评估了构造有效性,区分有效性,收有效性和测试-重新测试可靠性.
主要成果:
- 类固醇PRO被改进为15项尺度,有四个子尺度:社会影响,外表影响,心理影响和治疗问题.
- 拉什模型证实了四个子尺度结构和总得分,证明了构造的有效性和可靠性.
- 测试重复测试的可靠性非常好,其类内相关系数为0.809.
结论:
- 类固醇PRO是一个有效和可靠的15项尺度.
- 它有效地衡量了葡萄糖皮质类药物治疗在风湿性疾病患者的健康相关生活质量影响.
相关概念视频
Assessment of the Gastrointestinal System I: Subjective Data
202
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
202
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
122
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
122


